Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950401 | 0.88 | GPR119 (0.36) | LMNACYP2C9HRH3 | |
| SCHEMBL12026451 | 0.84 | HRH3 (0.40) | OPRL1OPRD1OPRK1L3MBTL3MBTD1 | |
| SCHEMBL20655373 | 0.82 | L3MBTL3 (0.46) | L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL24755111 | 0.78 | HRH3 (0.36) | L3MBTL3MBTD1L3MBTL1TACR1KCNH2 | |
| SCHEMBL26023136 | 0.78 | HRH3 (0.35) | OPRL1OPRD1OPRK1OPRM1HRH3 | |
| SCHEMBL14526648 | 0.77 | HRH3 (0.35) | OPRL1OPRD1OPRK1OPRM1HRH3 | |
| SCHEMBL21017349 | 0.77 | SMN1; SMN2 (0.38) | OPRL1L3MBTL3MBTD1L3MBTL1LMNA | |
| SCHEMBL25147438 | 0.75 | — | — | |
| SCHEMBL21310383 | 0.75 | — | — | |
| SCHEMBL23153455 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | OPRL1 3309/4885OPRD1 3037/4885OPRK1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.